Resources

Past Presentation

Hepatitis B Medications | February 22, 2023

Date of Presentation: February 22, 2023

Type: Past Presentation  

Audience: Clinical  

Program: Hepatitis C  

Keywords: #hbv  #hbv treatment  #hepatitis b  

In this presentation, Dr. Paulina Deming, ECHO faculty member and Associate Professor of Pharmacy at the University of New Mexico Sciences Center, discusses the current recommended medications for HBV treatment. She then differentiates between the recommended therapies for HBV. Learn more about the 5 x 5 x 5 Message regarding HBV below:

The 5 x 5 x 5 Message

Reasons to treat HBV
5 pillars

1.  Stigma/Discrimination
2.  QOL/extrahepatic diseases
3.  Infectivity
4.  CLD/cirrhosis Prevention
5.  HCC prevention

How to manage HBV :
Follow the 5 Line Guideline

1.  Test all for HBV with the HBV triple panel
2.  Vaccinate all for HBV who are triple panel negative
3.  Link all HBsAg+ patient to HBV DNA NAT testing and Delta Antibody screening
4.  All HBV DNA + patients are stated on Nuc therapy
5.  Stage all patients and decide on HBV surveillance

5 key messages about HBV
1.  HBV therapy is not life long, there are many new therapies in the pipeline that can lead to functional cure, HBsAg loss and HBV DNA(-)
2.  There are no “healthy” carriers, treatment results in improvement in the components of the 5 pillars
3.  We always need more “research”, but we have the research data now to take action now to implement the 5 line guideline
4.  Delta testing should be provided to all HBV + patients, D is for Deadly
5.  The only way forward to HBV elimination is to follow the 5 line guidelines, the current guidelines are too complex and lead to non-testing, non-treatment and non-vaccinations

Recording:

Presented by:

Dr. Paulina Deming

Dr. Paulina Deming is an Associate Professor-Clinical Educator within the Pharmacy Practice and Administrative Sciences Department at the College of Pharmacy at the University of New Mexico Health Sciences Center (UNMHSC). Dr. Deming completed a general practice residency and infectious diseases pharmacotherapy residency at UNMHSC. Her interests are focused in hepatitis C virus (HCV) infections and clinical therapeutics. She is the assistant director for the Project ECHO (Extension for Community Healthcare Outcomes) HCV clinic and serves on Project ECHO’s expert faculty panel advising providers on HCV care in community, corrections, and within the Indian Health Services settings. Licensed as a pharmacist clinician, she sees patients through the UNMHSC’s HCV clinic and the Truman HCV-HIV coinfection clinic. In addition to teaching and clinical work, Dr. Deming has co-authored papers on the management of HCV infections as well as HCV treatment outcomes in real-world settings.

Resources Provided:

Date added: February 22, 2023